Mark Ping Chao

14.8k citations
53 papers · 11.7k · 8 hit papers · h-index 29

Impact in

  • Immunology top 0.2%
    • Phagocytosis and Immune Regulation
    • Immune cells in cancer
    • Immunotherapy and Immune Responses
  • Hematology top 0.5%
    • Acute Myeloid Leukemia Research

Papers in

    • Acute Myeloid Leukemia Research 13
    • Hematopoietic Stem Cell Transplantation 2
    • Phagocytosis and Immune Regulation 15

Mark Ping Chao

52 papers receiving 11.4k citations

Mark Ping Chao's Hit Papers

Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study 2023 · 145 citations
1450+5+11Years since publication50010001.5k

Peers

Mark Ping Chao
Comparison fields: 5 of 79
  • Immunology 3.8k
  • Hematology 1.4k
  • Oncology 1.4k
  • Genetics 412
  • Pathology and Forensic Medicine 472
Replace Christopher Y. Park with:
Christopher Y. Park United States
Marc Schmitz Germany
David Avigan United States
Wolfram Brugger Germany
Natarajan Muthusamy United States
Jens-Peter Volkmer United States
Qing Yi United States
Amnon Peled Israel
Joshua Brody United States
Dan Eaton United States
Mark Ping Chao relative to Christopher Y. Park United States Christopher Y. Park's profile →
Citations per field
00.5×1.5×2×2.4×
Christopher Y. Park · 1×
Citations per year

Countries citing papers authored by Mark Ping Chao

Since Specialization
Citations

This map shows the geographic impact of Mark Ping Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Ping Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Ping Chao more than expected).

Fields of papers citing papers by Mark Ping Chao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Ping Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Ping Chao. The network helps show where Mark Ping Chao may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Ping Chao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Ping Chao Line = papers co-authored together Mark Ping Chao links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 53 papers — load more, or switch the sort, to bring in the rest.

#Work
1
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Hit paper breakdown →
20091500
2
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Hit paper breakdown →
20121434
3
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Hit paper breakdown →
20091341
4
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Hit paper breakdown →
2018943
5
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Hit paper breakdown →
2010940
6 2010668
7 2012561
8
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells
Hit paper breakdown →
2009547
9
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
Hit paper breakdown →
2019506
10 2015422
11 2010327
12 2011272
13 2006249
14 2011220
15 2010218
16 2020218
17 2011168
18
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
Hit paper breakdown →
2023145
19 2012131
20
Energy-Dense versus Routine Enteral Nutrition in the Critically Ill
2019115

About Mark Ping Chao

Mark Ping Chao is a scholar working on Hematology, Immunology, Genetics, Pathology and Forensic Medicine and Oncology, having authored 53 papers that have together received 11.7k indexed citations. Recurring topics across this work include Phagocytosis and Immune Regulation (15 papers), Acute Myeloid Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (2 papers), Alzheimer's disease research and treatments (2 papers), Hematopoietic Stem Cell Transplantation (2 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (2 papers), Pluripotent Stem Cells Research (1 paper) and Cancer Cells and Metastasis (1 paper). The work is most often cited by research in Immunology (3.8k citations), Hematology (1.4k citations), Oncology (1.4k citations), Genetics (412 citations) and Pathology and Forensic Medicine (472 citations). Mark Ping Chao has collaborated with scholars based in United States, United Kingdom and India. Frequent co-authors include Irving L. Weissman, Ravindra Majeti, Siddhartha Jaiswal, Ash A. Alizadeh, Wendy W. Pang, Nico van Rooijen, Christopher Y. Park, Kenneth D. Gibbs, Catriona H. M. Jamieson and David J. Traver. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, New England Journal of Medicine, Cell and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact